Federal Circuit Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution; Decision Prevents Approval of Teva ANDA
Mylan surges, Teva slumps after FDA approves Copaxone copy | Reuters.com
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Teva's recall of U.S.-made drugs latest example of contamination fears in generic marketplace; report says Lilly, Pfizer and former Mylan plant in Morgantown have been cited in the past | WV News
How Mylan tried to keep Teva from selling a generic EpiPen
Mylan Rejects Teva Buyout Offer
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Drugmaker Teva makes $40B bid for rival Mylan
Lawmakers to Teva, Mylan: Stop stonewalling our price-fixing probe | Fierce Pharma
$40B deal: Teva offers to buy Mylan
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Teva makes $40B offer for Mylan
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Valsartan recall expands to Mylan, Teva products | Fierce Pharma
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Mylan NV and Teva Pharmaceutical Industries Ltd decline as report says generic-drug companies face probe of alleged price fixing
Mylan, Generic Copaxone Punish Teva (NYSE:TEVA) | Seeking Alpha
Teva makes $40 billion offer for Mylan
Teva launches generic EpiPen in the U.S. | Fierce Biotech
Teva, Mylan to jumpstart production of old malaria drug to fight coronavirus
Teva Offers to Buy Mylan for $40 Billion - WSJ
Drugmaker Teva makes $40B bid for rival Mylan
